AmirMehrvarz SarshekehMD

Clinical Fellow - Hematology/Oncology

Dr. Mehrvarz Sarshekeh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1717 13th St
Ste 300
Everett, WA 98201
Phone+1 713-566-4550

Fax+1 425-297-5561

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2017
Tehran University of Medical Sciences School of MedicineClass of 2003, MD

PubMed

18 citations
Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.
Shailesh Advani, Pragati Shailesh Advani, Derek Brown, Stacia M. DeSantis, Krittiya Korphaisarn
BMC Cancer. 2019-10-17
37 citations
High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients
Bruno Conte, Ben George, Michael J. Overman, Jeannelyn S. Estrella, Zhi-Qin Jiang
Clinical Colorectal Cancer. 2016-06-01
28 citations
Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Amir Mehrvarz Sarshekeh, Michael J. Overman, Scott Kopetz
Future Oncology. 2018-02-23

Lectures

ARID1A mutation to define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
Association of TGF-Î² expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer.
2019 ASCO Annual Meeting - 6/1/2019
The characteristics of ARID1A mutations in colorectal cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018